|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PEX16 |
Gene summary for PEX16 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PEX16 | Gene ID | 9409 |
| Gene name | peroxisomal biogenesis factor 16 | |
| Gene Alias | PBD8A | |
| Cytomap | 11p11.2 | |
| Gene Type | protein-coding | GO ID | GO:0006605 | UniProtAcc | Q9Y5Y5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9409 | PEX16 | LZE2T | Human | Esophagus | ESCC | 4.08e-02 | 3.16e-01 | 0.082 |
| 9409 | PEX16 | LZE4T | Human | Esophagus | ESCC | 6.20e-07 | 2.05e-01 | 0.0811 |
| 9409 | PEX16 | LZE5T | Human | Esophagus | ESCC | 4.76e-06 | 2.33e-01 | 0.0514 |
| 9409 | PEX16 | LZE7T | Human | Esophagus | ESCC | 1.18e-05 | 2.71e-01 | 0.0667 |
| 9409 | PEX16 | LZE8T | Human | Esophagus | ESCC | 8.08e-29 | 7.85e-01 | 0.067 |
| 9409 | PEX16 | LZE20T | Human | Esophagus | ESCC | 3.54e-13 | 1.83e-01 | 0.0662 |
| 9409 | PEX16 | LZE22T | Human | Esophagus | ESCC | 6.09e-03 | 2.89e-01 | 0.068 |
| 9409 | PEX16 | LZE24T | Human | Esophagus | ESCC | 1.45e-28 | 6.27e-01 | 0.0596 |
| 9409 | PEX16 | LZE21T | Human | Esophagus | ESCC | 3.02e-03 | 1.35e-01 | 0.0655 |
| 9409 | PEX16 | LZE6T | Human | Esophagus | ESCC | 7.93e-06 | 2.49e-01 | 0.0845 |
| 9409 | PEX16 | P1T-E | Human | Esophagus | ESCC | 9.10e-12 | 3.18e-01 | 0.0875 |
| 9409 | PEX16 | P2T-E | Human | Esophagus | ESCC | 5.53e-19 | 3.40e-01 | 0.1177 |
| 9409 | PEX16 | P4T-E | Human | Esophagus | ESCC | 7.75e-20 | 3.11e-01 | 0.1323 |
| 9409 | PEX16 | P5T-E | Human | Esophagus | ESCC | 1.27e-17 | 3.54e-01 | 0.1327 |
| 9409 | PEX16 | P8T-E | Human | Esophagus | ESCC | 1.86e-24 | 4.64e-01 | 0.0889 |
| 9409 | PEX16 | P9T-E | Human | Esophagus | ESCC | 7.43e-20 | 4.32e-01 | 0.1131 |
| 9409 | PEX16 | P10T-E | Human | Esophagus | ESCC | 1.36e-14 | 2.02e-01 | 0.116 |
| 9409 | PEX16 | P11T-E | Human | Esophagus | ESCC | 5.15e-19 | 6.38e-01 | 0.1426 |
| 9409 | PEX16 | P12T-E | Human | Esophagus | ESCC | 1.71e-20 | 3.46e-01 | 0.1122 |
| 9409 | PEX16 | P15T-E | Human | Esophagus | ESCC | 1.63e-21 | 3.82e-01 | 0.1149 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0072594110 | Esophagus | ESCC | establishment of protein localization to organelle | 311/8552 | 422/18723 | 3.02e-32 | 2.13e-29 | 311 |
| GO:0006605111 | Esophagus | ESCC | protein targeting | 229/8552 | 314/18723 | 4.93e-23 | 1.01e-20 | 229 |
| GO:0090150110 | Esophagus | ESCC | establishment of protein localization to membrane | 182/8552 | 260/18723 | 1.27e-15 | 8.19e-14 | 182 |
| GO:001703818 | Esophagus | ESCC | protein import | 149/8552 | 206/18723 | 5.90e-15 | 3.31e-13 | 149 |
| GO:00718069 | Esophagus | ESCC | protein transmembrane transport | 47/8552 | 59/18723 | 9.02e-08 | 1.51e-06 | 47 |
| GO:00224069 | Esophagus | ESCC | membrane docking | 62/8552 | 86/18723 | 5.93e-07 | 7.79e-06 | 62 |
| GO:00650026 | Esophagus | ESCC | intracellular protein transmembrane transport | 40/8552 | 51/18723 | 1.76e-06 | 2.08e-05 | 40 |
| GO:00447433 | Esophagus | ESCC | protein transmembrane import into intracellular organelle | 29/8552 | 36/18723 | 1.91e-05 | 1.67e-04 | 29 |
| GO:00066124 | Esophagus | ESCC | protein targeting to membrane | 83/8552 | 131/18723 | 3.31e-05 | 2.73e-04 | 83 |
| GO:00440918 | Esophagus | ESCC | membrane biogenesis | 38/8552 | 55/18723 | 3.78e-04 | 2.19e-03 | 38 |
| GO:00066252 | Esophagus | ESCC | protein targeting to peroxisome | 14/8552 | 18/18723 | 5.77e-03 | 2.14e-02 | 14 |
| GO:00726622 | Esophagus | ESCC | protein localization to peroxisome | 14/8552 | 18/18723 | 5.77e-03 | 2.14e-02 | 14 |
| GO:00726632 | Esophagus | ESCC | establishment of protein localization to peroxisome | 14/8552 | 18/18723 | 5.77e-03 | 2.14e-02 | 14 |
| GO:00435742 | Esophagus | ESCC | peroxisomal transport | 16/8552 | 22/18723 | 9.46e-03 | 3.28e-02 | 16 |
| GO:007259412 | Liver | Cirrhotic | establishment of protein localization to organelle | 189/4634 | 422/18723 | 1.01e-19 | 2.45e-17 | 189 |
| GO:00066057 | Liver | Cirrhotic | protein targeting | 148/4634 | 314/18723 | 3.86e-18 | 6.20e-16 | 148 |
| GO:00901507 | Liver | Cirrhotic | establishment of protein localization to membrane | 123/4634 | 260/18723 | 1.85e-15 | 2.15e-13 | 123 |
| GO:00718063 | Liver | Cirrhotic | protein transmembrane transport | 31/4634 | 59/18723 | 4.10e-06 | 6.90e-05 | 31 |
| GO:00224065 | Liver | Cirrhotic | membrane docking | 39/4634 | 86/18723 | 2.47e-05 | 3.22e-04 | 39 |
| GO:00170387 | Liver | Cirrhotic | protein import | 77/4634 | 206/18723 | 3.56e-05 | 4.32e-04 | 77 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa041467 | Esophagus | ESCC | Peroxisome | 55/4205 | 82/8465 | 1.04e-03 | 3.27e-03 | 1.68e-03 | 55 |
| hsa0414612 | Esophagus | ESCC | Peroxisome | 55/4205 | 82/8465 | 1.04e-03 | 3.27e-03 | 1.68e-03 | 55 |
| hsa041462 | Liver | Cirrhotic | Peroxisome | 36/2530 | 82/8465 | 4.79e-03 | 1.74e-02 | 1.07e-02 | 36 |
| hsa041463 | Liver | Cirrhotic | Peroxisome | 36/2530 | 82/8465 | 4.79e-03 | 1.74e-02 | 1.07e-02 | 36 |
| hsa041464 | Liver | HCC | Peroxisome | 58/4020 | 82/8465 | 1.57e-05 | 1.05e-04 | 5.85e-05 | 58 |
| hsa041465 | Liver | HCC | Peroxisome | 58/4020 | 82/8465 | 1.57e-05 | 1.05e-04 | 5.85e-05 | 58 |
| hsa041466 | Oral cavity | OSCC | Peroxisome | 47/3704 | 82/8465 | 9.01e-03 | 2.01e-02 | 1.03e-02 | 47 |
| hsa0414611 | Oral cavity | OSCC | Peroxisome | 47/3704 | 82/8465 | 9.01e-03 | 2.01e-02 | 1.03e-02 | 47 |
| hsa0414621 | Oral cavity | LP | Peroxisome | 33/2418 | 82/8465 | 1.48e-02 | 4.69e-02 | 3.03e-02 | 33 |
| hsa0414631 | Oral cavity | LP | Peroxisome | 33/2418 | 82/8465 | 1.48e-02 | 4.69e-02 | 3.03e-02 | 33 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PEX16 | deletion | Frame_Shift_Del | novel | c.2delT | p.Met1? | p.M1? | Q9Y5Y5 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| PEX16 | SNV | Missense_Mutation | c.653C>T | p.Thr218Ile | p.T218I | Q9Y5Y5 | protein_coding | tolerated(0.15) | possibly_damaging(0.688) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| PEX16 | SNV | Missense_Mutation | rs375900051 | c.542N>T | p.Thr181Met | p.T181M | Q9Y5Y5 | protein_coding | deleterious(0.01) | possibly_damaging(0.859) | TCGA-AZ-6601-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| PEX16 | SNV | Missense_Mutation | c.827G>A | p.Arg276His | p.R276H | Q9Y5Y5 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| PEX16 | SNV | Missense_Mutation | rs767624302 | c.196N>T | p.Arg66Trp | p.R66W | Q9Y5Y5 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-DM-A1D4-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| PEX16 | SNV | Missense_Mutation | novel | c.952N>C | p.Thr318Pro | p.T318P | Q9Y5Y5 | protein_coding | tolerated_low_confidence(0.11) | benign(0.059) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| PEX16 | SNV | Missense_Mutation | rs774218187 | c.592C>T | p.Arg198Trp | p.R198W | Q9Y5Y5 | protein_coding | tolerated(0.08) | possibly_damaging(0.648) | TCGA-AJ-A3BH-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
| PEX16 | SNV | Missense_Mutation | novel | c.676G>A | p.Ala226Thr | p.A226T | Q9Y5Y5 | protein_coding | tolerated(0.56) | benign(0.005) | TCGA-AJ-A3NE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| PEX16 | SNV | Missense_Mutation | rs542844862 | c.830N>A | p.Arg277Gln | p.R277Q | Q9Y5Y5 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PEX16 | SNV | Missense_Mutation | c.396N>T | p.Lys132Asn | p.K132N | Q9Y5Y5 | protein_coding | tolerated(0.16) | possibly_damaging(0.899) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |